{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-26-000005","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.479307+00:00","generated_at":"2026-05-16T02:54:34.763842+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"West Pharma Q4 adj EPS $2.04, +12.1% YoY; guides FY2026 $7.85-$8.20","bullets":["Q4 net sales $805M (+7.5% reported, +3.3% organic); HVP Components $389.8M (+20.3%, +15.1% organic).","Full-year 2025: net sales $3.074B (+6.3%); diluted EPS $6.79 (+1.5%), adj-diluted EPS $7.29 (+8.0%).","FY2026 guidance: net sales $3.215B-$3.275B (4.6%-6.5% growth); adj-diluted EPS $7.85-$8.20 (+7.7%-12.5%).","Operating cash flow $754.8M (+15.5%); free cash flow $468.9M (+69.6%); repurchased 552,593 shares for $134M.","Expects mid-2026 close of SmartDose 3.5mL sale to AbbVie; device generated $55M in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-26-000005","json":"https://secwatch.observer/filing/0000105770-26-000005.json","markdown":"https://secwatch.observer/filing/0000105770-26-000005.md","text":"https://secwatch.observer/filing/0000105770-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/0000105770-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/wst-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:54:34.763842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}